IMO the FDA has been in the process of reviewing the current trial data. asking questions on the data and getting answers from IONIS & BIOGEN. The changing of the trial endpoints and stopping trial enrollment is significant and would not have occurred without a lot of analysis by the FDA. We are in clean -up mode with the FDA to stopping the trial and proceeding to filing NDA.
By the way these stupid shorts are going to have to cover under some serious upward movement in the stock price "Good luck To them"
Sentiment: Strong Buy
Only a fool would rely on what the analyst say, its way to early in the RG-101 functional cure cycle as we have not even seen 12 week data let alone 48 week results a functional cure
Always do your own DD before investing a single penny in any stock
The stock is worth maybe $12 based on positive 12 week RG-101 data in June given the current biotech sector blues and the HepC landscape.